ArticleFrontiers in endocrinology2025
Zinc sulfate improves insulin resistance, oxidative stress and apoptosis in liver tissues of PCOS rats through the NF-κB pathway.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Reproductive and Cardiometabolic Characterization of a Letrozole- and High-Fat Diet-Induced PMOS-like Rat Model: An Experimental Study.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Stigmasterol ameliorates obesity-associated insulin resistance by activating the PPARγ pathway and alleviating oxidative stress.Frontiers in endocrinology · 2026Article
- Nutrients and bioactive compounds in polycystic ovary syndrome: updated insights into effects and underlying mechanisms.Frontiers in nutrition · 2026Review
- Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential.Frontiers in endocrinology · 2026Review
- The mediating effect of serum total testosterone in the association between the ZJU index and PCOS.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) is primarily characterized by insulin resistance, which leads to increased hepatic glucose production and impaired insulin-mediated glucose disposal. Pathologically, this condition manifests as elevated liver cell apoptosis and reduced lipid transport capacity, further exacerbating insulin resistance. Liver cell apoptosis and mitochondrial dysfunction are key pathological features of PCOS-associated liver diseases, contributing significantly to the progression of PCOS. Although zinc sulfate is recognized for its antioxidant properties, its efficacy in ameliorating PCOS-related liver damage remains unclear. Methods: Female Sprague-Dawley rats were induced with PCOS and non-alcoholic fatty liver disease (NAFLD) through a high-fat diet and letrozole administration over 28 days. Subsequently, the model rats received zinc sulfate treatment via gavage once daily for an additional 21 days. Serum hormone levels and biochemical markers were assessed using ELISA and enzymatic assays. Histological examination of ovarian and liver tissues was performed using hematoxylin and eosin (HE) staining, while hepatic lipid accumulation was evaluated by Oil Red O staining. Transmission electron microscopy was employed to examine liver cell ultrastructure, and TUNEL staining was used to assess hepatocellular apoptosis. Transcriptome sequencing was conducted on liver tissues to identify key genes and pathways, which were further validated by Western blotting and immunohistochemistry. Results: Initial blood sampling revealed decreased serum zinc concentration in the PCOS group, alongside elevated levels of testosterone (T), luteinizing hormone (LH), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglycerides (TG), total cholesterol (TC), blood glucose, fasting insulin, and oral glucose tolerance test (OGTT) values. However, the levels of serum estrogen (E2) and follicle-stimulating hormone (FSH) in the PCOS group were significantly decreased. Markers of oxidative stress, including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione disulfide/glutathione ratio (GSSG/GSH), glutathione peroxidase (GSH-PX), and catalase (CAT), were also increased. Zinc sulfate treatment effectively improved all these parameters. HE and Oil Red O staining confirmed that zinc sulfate mitigated high-fat diet and letrozole-induced fatty liver. Furthermore, zinc sulfate alleviated severe hepatocellular apoptosis and mitochondrial damage observed in PCOS rats. Transcriptomic analysis indicated that zinc sulfate primarily mitigated PCOS-related liver damage via the cholesterol synthesis pathway, and experimental validation demonstrated that zinc sulfate inhibited oxidative stress and apoptosis in liver cells through the NF-κB pathway. Conclusion: Our study demonstrates that zinc sulfate ameliorates liver oxidative stress and apoptosis in PCOS by modulating the NF-κB pathway, offering a novel therapeutic approach for managing PCOS-associated liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.